EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Landscape of Prophylactic Strategies Against Human Parainfluenza Virus Type 3

Clémence Vacher, Julia Dubois iD, Marie-Eve Hamelin iD, Guy Boivin, Manuel Rosa-Calatrava iD

Reviews in Medical Virology · 2025-11 · 35 (6)

DOI: 10.1002/rmv.70071 ↗

At a glance

Übersichtsarbeit in Reviews in Medical Virology, published online on 2025-10-09. Written by Clémence Vacher and 4 co-authors. Institution: CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Inserm, Université Claude Bernard Lyon 1, CNRS, ENS de Lyon, Lyon, France. Major MEDLINE topics: Parainfluenza Virus 3, Human, Respirovirus Infections, Parainfluenza Vaccines. Cited 6 times so far (Crossref); 104 references. The full text is freely available (open access, CC BY 4.0). Funded by: CIHR.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Human parainfluenza virus‐type 3 (HPIV3) is a respiratory virus responsible for mild illnesses in most of the population and severe illnesses, such as bronchiolitis and pneumonia, in young children, immunocompromised individuals and the elderly. To date, no vaccines nor antiviral drugs have been approved against HPIV3, despite its significant burden in vulnerable people. In this review, we present both past and current prophylactic strategies against HPIV3, such as live‐attenuated virus, vector‐based, subunit and mRNA vaccine candidates or antibody‐based passive protection. For each strategy, we give an overview of the most promising candidates evaluated in preclinical studies and we report immunogenicity and protection data from clinical trials. Finally, we discuss the most important challenges regarding those vaccine strategies and their potential administration to the different vulnerable populations.

Subjects

MeSH terms (MEDLINE)

Parainfluenza Virus 3, HumanRespirovirus InfectionsParainfluenza VaccinesHumansAnimalsVaccines, AttenuatedClinical Trials as TopicAntibodies, Viral

Author keywords

monoclonal antibodiesparainfluenza virus type 3respiratory infectionsvaccine candidates

Substances

Vaccines, AttenuatedParainfluenza VaccinesAntibodies, Viral

Authors and institutions

  • CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Inserm, Université Claude Bernard Lyon 1, CNRS, ENS de Lyon, Lyon, France.
  • Centre de Recherche en Infectiologie of the Centre Hospitalier Universitaire de Québec and Université Laval, Québec, QC, Canada.
  • International Research Laboratory RESPIVIR France - Canada, Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC, Canada.
  • Centre International de Recherche en Infectiologie, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, INSERM, CNRS, ENS de Lyon, Lyon, France.
  • Virnext, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Lyon, France.

ORCID profiles: Julia Dubois, Marie-Eve Hamelin, Manuel Rosa-Calatrava

Funding

  • CIHR

Cite

APA

Vacher, C., Dubois, J., Hamelin, M. E., Boivin, G., & Rosa-Calatrava, M. (2025). Landscape of Prophylactic Strategies Against Human Parainfluenza Virus Type 3. Reviews in Medical Virology, 35(6). https://doi.org/10.1002/rmv.70071

Vancouver

Vacher C, Dubois J, Hamelin ME, Boivin G, Rosa-Calatrava M. Landscape of Prophylactic Strategies Against Human Parainfluenza Virus Type 3. Reviews in Medical Virology. 2025;35(6). doi:10.1002/rmv.70071

BibTeX
@article{Vacher2025,
  author = {Vacher, Clémence and Dubois, Julia and Hamelin, Marie-Eve and Boivin, Guy and Rosa-Calatrava, Manuel},
  title = {Landscape of Prophylactic Strategies Against Human Parainfluenza Virus Type 3},
  journal = {Reviews in Medical Virology},
  year = {2025},
  volume = {35},
  number = {6},
  doi = {10.1002/rmv.70071}
}
Start for free →